Attune Medical’s ensoETM is a single use thermal regulating device that is placed in the esophagus similar to a standard gastric tube and connected to an external heat exchange unit, creating a closed-loop system for heat transfer to increase or decrease patient temperature. Its placement in the esophagus, with proximity to blood flow from the heart and great vessels, allows highly efficient heat transfer. EPs are now looking at the device as a way to prevent RF damage to the esophagus during ablations.

Attune Medical’s ensoETM is a single use thermal regulating device that is placed in the esophagus similar to a standard gastric tube and connected to an external heat exchange unit, creating a closed-loop system for heat transfer to increase or decrease patient temperature. EPs are now looking at the device as a way to prevent RF damage to the esophagus during cardiac ablations.
 

News | EP Lab | December 03, 2020
December 3, 2020 – Attune Medical reports the first major peer-reviewed clinical publication using its ensoETM device...
An example of a body composition analysis of an abdominal CT slice with the subcutaneous fat in green, skeletal muscle red and visceral fat in yellow. This was automatically identified and analyzed via a deep learning algorithm to assess the risk for heart attack and stroke in more than 12,000 patients. #RSNA2020 #RSNA20 #RSNA

An example of a body composition analysis of an abdominal CT slice with the subcutaneous fat in green, skeletal muscle red and visceral fat in yellow. This was automatically identified and analyzed via a deep learning algorithm to assess the risk for heart attack and stroke in more than 12,000 patients.

Feature | Artificial Intelligence | December 02, 2020
December 2, 2020 – Automated deep learning analysis of abdominal computed tomography (CT) images produces a more...
cyanosis, cyantosis COVID-positive infant.

Chest X-ray of a  2-month-old infant diagnosed with COVID-19 showing an enlarged heart, bibasilar opacities caused by collapse of the lower sections of lungs, and right upper lobe atelectasis (lung collapse). Find more information anf figures on this patient case.

 

News | Coronavirus (COVID-19) | December 02, 2020
December 2, 2020 — A 2-month-old infant diagnosed with COVID-19 (SARS-CoV-2) experienced reversible myocardial injury...
CMS coverage changes effective as of Dec. 2, 2020 will open up the use of LVADs to more Medicare patients, including use of the HeartWare and HeartMate ventricular assist devices.

CMS coverage changes effective as of Dec. 2, 2020 will open up the use of LVADs to more Medicare patients, including use of the HeartWare and HeartMate ventricular assist devices.

News | Heart Failure | December 02, 2020
December 2, 2020 — The Centers for Medicare and Medicaid Services (CMS) finalized updates to Medicare coverage policies...
GE Healthcare is introducing a new, smaller and lighter weight robotic driven angiography system for image guided therapy, the Allia IGS 7 angiography system. #RSNA20 #RSNA2020

The GE Healthcare Allia IGS 7 angiography system.

News | Angiography | December 01, 2020
December 3, 2020 — GE Healthcare is introducing a new version of its robotic driven angiography system for image guided...
Medical imaging artificial intelligence (AI) vendor Avicenna.AI today announced its FDA-cleared CINA Head triage AI solution will be offered by cloud-based imaging platform Arterys. Supporting the treatment of stroke and neurovascular emergencies, CINA Head detects intracranial hemorrhages (ICHs) and large vessel occlusions (LVOs) from CT-scan imaging. #RSNA20 #RSNA2020

Medical imaging artificial intelligence (AI) vendor Avicenna.AI today announced its FDA-cleared CINA Head triage AI solution will be offered by cloud-based imaging platform Arterys. Supporting the treatment of stroke and neurovascular emergencies, CINA Head detects intracranial hemorrhages (ICHs) and large vessel occlusions (LVOs) from CT-scan imaging.
 

News | Stroke | December 01, 2020
December 1, 2020 – Medical imaging artificial intelligence (AI) vendor Avicenna.AI today announced its FDA-cleared CINA...
COVID-19 cardiology related content continues to be among the top performers on the DAIC website in November 2020. TAVR also topped headlines with Boston Scientific taking its Lotus valve off the market and a review of TAVR registry data showing it is now the dominant method of aortic valve replacement in the United States. #DAIC

COVID-19 cardiology related content continues to be among the top performers on the DAIC website in November 2020. TAVR also topped headlines with Boston Scientific taking its Lotus valve off the market and a review of TAVR registry data showing it is now the dominant method of aortic valve replacement in the United States.

Feature | Cardiovascular Business | December 01, 2020 | Dave Fornell, Editor
December 1, 2020 — Here is the list of the most popular content on the Diagnostic and Interventional Cardiology (DAIC)...
A recent publication demonstrated procedural efficiency for MitraClip transcatheter mitral valve repair (TMVR) with use of the Baylis VersaCross RF Transseptal Solution, reporting guide delivery from femoral access in under 7.5 minutes.
News | Hemodynamic Monitoring Systems | December 01, 2020
December 1, 2020 — A recent publication demonstrated procedural efficiency for MitraClip transcatheter mitral valve...
The Clarius PA HD hand-held, wireless ultrasound scanner is now available for high resolution cardiac imaging with the release of the Clarius Ultrasound App 7.3 for iOS and Android smart devices.
News | Cardiovascular Ultrasound | November 30, 2020
November 30, 2020 — The Clarius PA HD hand-held, wireless ultrasound scanner is now available for high resolution...
The U.S. Food and Drug Administration (FDA) has cleared AliveCor's Kardia AI V2 next generation of interpretive artificial intelligence (AI)-based personal electrocardiogram (ECG) algorithms.

The U.S. Food and Drug Administration (FDA) has cleared AliveCor's Kardia AI V2 next generation of interpretive artificial intelligence (AI)-based personal electrocardiogram (ECG) algorithms.

News | Artificial Intelligence | November 24, 2020
November 24, 2020 — The U.S. Food and Drug Administration (FDA) has cleared AliveCor's next generation of interpretive...
One-year results off the PIONEER III study comparing the safety and efficacy of the Supreme HT drug-eluting stent (DES), to the Xience or Promus Durable Polymer DES showed it was equivalent in clinical performance to the market-leading DES. The results were presented at the 2020 American Heart Association (AHA) Scientific Session. #AHA2020 #AHA20 #AHA

One-year results off the PIONEER III study comparing the safety and efficacy of the Supreme HT drug-eluting stent (DES), to the Xience or Promus Durable Polymer DES showed it was equivalent in clinical performance to the market-leading DES. The results were presented at the 2020 American Heart Association (AHA) Scientific Session.

News | Stents | November 24, 2020
November 24, 2020 — One-year results off the PIONEER III study comparing the safety and efficacy of the Supreme HT (...
Leveraging the Right Image and Reporting Platform in Cardiology for Optimal Performance and Outcomes and picking a cardiovascular information system (CVIS).
Case Study | Cardiovascular Information Systems (CVIS) | November 23, 2020
This Frost & Sullivan Executive White Paper explains that digitization is the shift to value-based care and risk-...
Videos | Coronavirus (COVID-19) | November 18, 2020
Aaron Baggish, M.D., director of the cardiovascular performance program, Massachusetts General Hospital. He was on a...
Results from study of more than 14,000 patients across the United States show the heavy impact of cardiac disease on hospitalized COVID patients. COVID-19 patients with cardiovascular diseases have in-hospital mortality rates of between 25 to 38 percent. #AHA #AHA20 #AHA2020 #COVID19 #Coronavirus #SARSCoV2

Results from study of more than 14,000 patients across the United States show the heavy impact of cardiac disease on hospitalized COVID patients. COVID-19 patients with cardiovascular diseases have in-hospital mortality rates of between 25 to 38 percent. 

News | Coronavirus (COVID-19) | November 18, 2020 | Dave Fornell, Editor
November 18, 2020 — A late-breaking study at the 2020 American Heart Association (AHA) Scientific Sessions showed...
RIVER trial is the largest study assessing the efficacy and safety of the anticoagulant rivaroxaban in patients with an artificial mitral valve to correct an irregular heart rhythm
News | November 18, 2020
November 18, 2020 — The primary results from the RIVER Trial, Rivaroxaban for Valvular Heart disease and Atrial...